$18.480
+0.030 (+0.16%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
VTRS 相似圖表分析預測
Alphio's VTRS stock price prediction model matches the current Viatris Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $18.68 (+1.09%). The 1-week path is $18.53 (+0.27%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 Viatris Inc 股票嗎?
Viatris Inc is a good buy right now due to its recent FDA approval for RYZUMVI, which is expected to drive revenue growth, and a strong forward P/E ratio of 6.38, suggesting the stock is undervalued. Additionally, the stock has shown a year-to-date change of +49.72%, indicating strong momentum. However, the main risk is the significant insider selling, which has increased by 247.32% over the last quarter, suggesting potential concerns about future performance.
VTRS 股價於 Thursday 收在 $18.48,此前上漲 +0.16%
Viatris Inc (VTRS) last closed at $18.48, gaining +0.16%. These facts feed the 1-day and 1-week VTRS price prediction above.
預測驅動因素
Viatris Inc(VTRS)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bullish
SMA 200
Bullish
相似圖表形態
近期走勢與 VTRS 最接近的股票,依相似度排序。
VTRS 季節性分析
Historically the probability of a positive October return for VTRS is 62.90%. February offers the highest probability of a positive month at 67.24%, while June is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
VTRS 十年價格預測
| 月份 | 最低價 | 平均價 | 最高價 | 潛在報酬率 |
|---|---|---|---|---|
| Oct 2026 | $7.25 | $8.82 | $9.77 | -52.29% |
| Nov 2026 | $9.24 | $9.28 | $11.25 | -49.77% |
| Dec 2026 | $7.20 | $8.92 | $10.07 | -51.71% |
2026 年,Viatris Inc(VTRS)預計區間為 $7.20 至 $11.25。
Viatris Inc 2026 年月度預測
2026 年 Oct,Viatris Inc 預計均價 $8.82,最低 $7.25,最高 $9.77。
2026 年 Nov,Viatris Inc 預計均價 $9.28,最低 $9.24,最高 $11.25。
2026 年 Dec,Viatris Inc 預計均價 $8.92,最低 $7.20,最高 $10.07。
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。